Amir Marvasti, None;
Linda Zangwill, Carl Zeiss Meditec Inc (F), Heidelberg Engineering GmbH (F), Nidek Inc (F), Optovue Inc (F), Quark (F), Topcon Inc (F);
Ricardo Abe, None;
Alberto Diniz-Filho, None;
Carolina Gracitelli, None;
Robert Weinreb, Amatek (C), Nidek (F), Optovue (F), Aerie (F), Alcon (C), Allergan (C), Aquesys (C), Bausch & Lomb (C), Carl Zeiss Meditec Inc (F), Carl Zeiss Meditec, Inc. (C), Genentech (R), Quark (F), Topcon (F), Valeant (C);
Christopher Girkin, Carl Zeiss Meditech, Inc. (F), EyeSight Foundation of Alabama (F), Heidelberg Engineering, GmbH (F), National Eye Institute (F), Research to Prevent Blindness (F), SOLX (F);
Jeffrey Liebmann, Alcon, Inc. (C), Allergan, Inc. (C), Bausch & Lomb, Inc. (C), Bausch & Lomb, Inc. (F), Carl Zeiss Meditech, Inc. (F), Diopysis, Inc. (C), Diopysis, Inc. (F), Heidelberg Engineering, GmbH (C), Heidelberg Engineering, GmbH (F), Merz Pharmaceuticals, Inc. (C), Optovue, Inc. (F), Quark Pharmaceuticals, Inc (F), Reichert, Inc. (F), Sensimed, Inc. (F), Topcon, Inc. (F), Valeant Pharmaceuticals (C);
Felipe Medeiros, Alcon Laboratories Inc (F), Alcon Laboratories Inc. (C), Alcon Laboratories Inc. (R), Allergan Inc (C), Allergan Inc (F), Allergan Inc (R), Bausch & Lomb (F), Carl Zeiss Meditec Inc. (C), Carl Zeiss Meditec Inc. (F), Carl Zeiss Meditec Inc. (R), Heidelberg Engineering Inc (F), Merck (F), National Eye Institute (F), Novartis (C), Reichert, Inc (F), Reichert, Inc (R), Sensimed (F), Topcon Inc (F)